Research groups
Colleges
Jeremy Tomlinson
MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Key publications
-
Dual-5α-Reductase Inhibition Promotes Hepatic Lipid Accumulation in Man.
Journal article
Hazlehurst JM. et al, (2016), J Clin Endocrinol Metab, 101, 103 - 113
-
Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
Journal article
Armstrong MJ. et al, (2016), J Hepatol, 64, 399 - 408
-
5α-Reductase Type 2 Regulates Glucocorticoid Action and Metabolic Phenotype in Human Hepatocytes.
Journal article
Nasiri M. et al, (2015), Endocrinology, 156, 2863 - 2871
Recent publications
-
New Approaches to the Treatment of Hypercortisolism.
Journal article
Pofi R. et al, (2024), Annu Rev Med
-
Lessons to learn from the 2024 NICE guideline on adrenal insufficiency.
Journal article
Dong J. and Tomlinson JW., (2024), Lancet Diabetes Endocrinol
-
Prospective cohort for early detection of liver cancer (Pearl): a study protocol.
Journal article
Khanna K. et al, (2024), BMJ Open, 14
-
Dissociation between liver fat content and fasting metabolic markers of selective hepatic insulin resistance in humans
Journal article
Westcott F. et al, (2024), European Journal of Endocrinology (EJE)
-
Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain
Preprint
Hodson D. et al, (2024)